TABLE 4.
Condition or disease | Drugs | Study phase | Status | Identifier |
---|---|---|---|---|
Alcoholism | Disulfiram | Not applicable | Unknown | NCT00431262 |
Alcohol‐related disorders | Disulfiram | Not applicable | Completed | NCT00142844 |
Cocaine‐related disorders | Naltrexone | |||
Alcohol dependence | Disulfiram | Not applicable | Completed | NCT00721526 |
Anxiety disorder | Lorazepam | |||
Alcohol addiction | Disulfiram | Not applicable | Completed | NCT03212599 |
Alzheimer's disease | ||||
Recurrent GBM | Disulfiram/copper | Phase II | Completed | NCT03034135 |
Temozolomide | ||||
GBM | Disulfiram/copper | Phase II | Not yet recruiting | NCT01777919 |
Temozolomide | ||||
Metastatic breast cancer | Disulfiram | Phase II | Recruiting | NCT04265274 |
Chemotherapy | ||||
NSCLC | Disulfiram | Phase II/III | Completed | NCT00312819 |
Chemotherapy |
Abbreviations: GBM, glioblastoma; NSCLC, non‐small cell lung cancers.
Source: clinicaltrials.gov website.